October 1, 2020
BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson’s Disease Programs
BIAL Biotech to be based in Cambridge, Massachusetts and will be a ResearchCenter of Excellence dedicated to genetically-defined Parkinson’s disease• LTI-291 clinical program and other research programs in Parkinson's diseaseacquired…
August 21, 2020
Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering
WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins…
August 19, 2020
Trefoil Therapeutics Begins First Clinical Trial of Regenerative Treatment for Patients with Corneal Endothelial Dystrophies
Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells August 19, 2020 07:00 AM Eastern Daylight Time SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics today…
August 14, 2020
Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis
Therapy currently being evaluated in Phase I/II clinical study Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness DURHAM, N.C.,…
July 9, 2020
Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients
– Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments – – Kymera to retain option during clinical development to participate equally in US…
June 15, 2020
Shattuck Labs Announces Closing of $118 Million Series B Financing
Financing will advance two ARC™ clinical programs and expand pipeline development -- DURHAM, NC and AUSTIN, TX – June 15, 2020 – Shattuck Labs, Inc. (“Shattuck”), a clinical-stage…
May 27, 2020
PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients
PhaseBio receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program (CTAP) “VANGARD” trial will assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk…
April 28, 2020
AtaCor Medical Secures $25M Financing to Continue Extracardiac Pacing Development
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. announced today that is has completed a $25M Series B financing. The financing syndicate, led by a corporate partner, includes existing investors Broadview Ventures and…
April 23, 2020
Nature Communications Highlights Research by Scientists at Graybug Vision and Johns Hopkins University on Sustained Treatment of Retinal Diseases
REDWOOD CITY, Calif., April 21, 2020 – Graybug Vision, Inc., a clinical stage biopharmaceutical company focused on developing transformative medicines to treat vision-threatening diseases of the retina and optic nerve,…
March 12, 2020
Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
CAMBRIDGE, Mass., March 12, 2020 /PRNewswire/ -- Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C…